Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19599246 | 0.95 | PSMB8 (0.42) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL21317603 | 0.92 | PSMB8 (0.53) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL18811687 | 0.92 | PSMB8 (0.53) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL18811689 | 0.92 | PSMB8 (0.53) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL17725885 | 0.86 | PSMB8 (0.36) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL23512695 | 0.84 | CHRNA4 (0.39) | PSMB8PSMB9PSMB5SMYD3GPR65 | |
| Hydrochloric Acid SCHEMBL23500999 | 0.83 | CHRNA4 (0.38) | PSMB8PSMB9PSMB5SMYD3GPR65 | |
| Hydrochloric Acid SCHEMBL23501001 | 0.83 | CHRNA4 (0.38) | PSMB8PSMB9PSMB5SMYD3GPR65 | |
| SCHEMBL27667662 | 0.83 | PSMB8 (0.47) | PSMB8PSMB9PSMB5SMN1; SMN2LMNA | |
| SCHEMBL23026123 | 0.83 | PSMB8 (0.44) | PSMB8PSMB9PSMB5LMNAPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116615425-A | Compounds and compositions as Sppl2a inhibitors | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | PSMB8 430/4885PSMB9 559/4885PSMB5 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.